A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

NCT02033889 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

621

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ertugliflozin 5 mg
DRUG: Ertugliflozin 15 mg
DRUG: Placebo to Ertugliflozin
OTHER: Glimepiride
DRUG: Placebo to Glimepiride
BIOLOGICAL: Basal Insulin
DRUG: Metformin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]